© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
ASCO Melanoma
ASCO Expert Discusses Clinical Benefit of Combination for Relapsed/Refractory Multiple Myeloma
June 02, 2020
Ajay K. Nooka, MD, MPH, FACP discussed the clinical benefits of belantamab mafodotin in combination with bortezomib/dexamethasone to treat multiple myeloma.
Dr. Anna Pavlick on Dendritic Cells vs Montanide in Melanoma Patients in Remission
June 20, 2019
Cancer Network spoke with Anna Pavlick, MD, of NYU Langone Health, on the results of a phase II study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared with Montanide.
Dr. Paul Chapman on the Choice to Pursue Adjuvant Immunotherapy for Melanoma Patients
June 19, 2019
Cancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan Kettering Cancer Center, about pursuing adjuvant immunotherapy for patients with melanoma.